Santoro, FrancescoNunez-Gil, Ivan JavierVitale, EnricaViana-Llamas, Maria C.Reche-Martinez, BegonaRomero-Pareja, RodolfoFeltez Guzman, GiselaFernandez Rozas, InmaculadaUribarri, AitorBecerra-Munoz, Victor ManuelAlfonso-Rodriguez, EmilioGarcia-Aguado, MarcosHuang, JiaOrtega-Armas, Maria ElizabethGarcia Prieto, Juan F.Corral Rubio, Eva MariaUgo, FabrizioBianco, MatteoMulet, AlbaRaposeiras-Roubin, SergioJativa Mendez, Jorge LuisEspejo Paeres, CarolinaAlbarran, Adrian RodriguezMarin, FranciscoGuerra, FedericoAkin, IbrahimCortese, BernardoRamakrishna, HarishMacaya, CarlosFernandez-Ortiz, AntonioBrunetti, Natale Daniele2025-01-072025-01-072021-10-051355-6037https://hdl.handle.net/10668/26896Background Standard therapy for COVID-19 is continuously evolving. Autopsy studies showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the study was therefore to evaluate the safety and efficacy of antiplatelet therapy (APT) in hospitalised patients with COVID-19 and its impact on survival.Methods 7824 consecutive patients with COVID-19 were enrolled in a multicentre international prospective registry (Health Outcome Predictive Evaluation-COVID-19 Registry). Clinical data and in-hospital complications were recorded. Data on APT, including aspirin and other antiplatelet drugs, were obtained for each patient.Results During hospitalisation, 730 (9%) patients received single APT (93%, n=680) or dual APT (7%, n=50). Patients treated with APT were older (74 +/- 12 years vs 63 +/- 17 years, penCOVID-19pharmacologyclinicalCoronavirus disease 2019research article34611045open access10.1136/heartjnl-2021-3195521468-201Xhttps://heart.bmj.com/content/heartjnl/108/2/130.full.pdf722678600001